SLDB
Solid Biosciences Inc.
$6.56
+1.38%
$637.0M
No data for this timeframe.
Vol
Market Cap$637.0M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (95%)
Inst. Holders8 funds
Inst. Value$37.6M
Inst. Activity2 buys / 3 sells
Insider Activity0B / 13S
Insider Net $-$2.3M
SEC Reports5
Press Releases5
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001707502·Prev Close $6.47
Recent Activity
May 14, 2026
short_volume
Short Volume: SLDB — 57.9% short (0.4M / 0.7M)
Short: 427,277 | Exempt: 842 | TRF Vol: 737,730 | Short Ratio: 57.9% | Off-exchange volume (dark poo
May 12, 2026
SEC
Solid Biosciences reported Q1 2026 EPS of -$0.53, a 20.9% miss versus the -$0.44 consensus, with net loss widening to $5
PRESS-RELEASE — Impact 6/10
Apr 23, 2026
SEC
Solid Biosciences is holding its 2026 annual meeting with several key proposals, including the ratification of Ilan Gano
DEFA14A — Impact 3/10
Apr 10, 2026
SEC
Solid Biosciences Inc. announced a board seat reclassification for director Ilan Ganot, who resigned from Class III and
8-K — Impact 2/10
Apr 2, 2026
Insider
SMITH IAN F sold 3,441 shares
Director @ $0.00 ($0.00)
Apr 2, 2026
Insider
SMITH IAN F sold 3,441 shares
Director @ $0.00 ($0.00)
Mar 9, 2026
Insider
PERCEPTIVE ADVISORS LLC sold 8,912,655 shares
Director @ $5.61 ($50.0M)
Inst.
FMR LLC — TRIM
2,029,898 shares ($11.4M)
Price Targets
$17.00
+159.2% upside
Strong Buy
Current $6.56
Low $11.00
Median $16.00
High $26.00
13 analysts
$11.00
$26.00
Analyst Ratings
8Strong Buy
11Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 18, 2026 | Wedbush | REITERATE | Outperform → Outperform |
| May 13, 2026 | Wedbush | MAINTAIN | Outperform → Outperform |
| May 13, 2026 | Piper Sandler | MAINTAIN | Overweight → Overweight |
| Mar 25, 2026 | JP Morgan | MAINTAIN | Overweight → Overweight |
| Mar 23, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.47 ▼ -14.9% | $-0.56 — $-0.36 | -12% YoY | 13 |
| Next Q | $-0.48 ▼ -14.0% | $-0.57 — $-0.39 | -1% YoY | 13 |
| Current FY | $-1.98 ▼ -15.0% | $-2.51 — $-1.67 | 1% YoY | 13 |
| Next FY | $-1.93 ▼ -14.4% | $-2.33 — $-1.36 | 3% YoY | 12 |
Latest Reports
BEARISH
PRESS-RELEASE
6/10
Solid Biosciences reported Q1 2026 EPS of -$0.53, a 20.9% miss versus the -$0.44 consensus, with net loss widening to $5
May 12, 2026
BULLISH
Press
7/10
Solid Biosciences dosed the first participant in its Phase 3 IMPACT DUCHENNE trial for SGT-003, a gene therapy for Duche
May 7, 2026
NEUTRAL
DEFA14A
3/10
Solid Biosciences is holding its 2026 annual meeting with several key proposals, including the ratification of Ilan Gano
Apr 23, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $19.5M | ADD |
| FMR LLC | $11.4M | TRIM |
| MORGAN STANLEY | $2.2M | ADD |
| BANK OF AMERICA CORP | $1.9M | TRIM |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $911.1K | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 2, 2026 | SMITH IAN | M | $0.00 |
| Apr 2, 2026 | SMITH IAN | M | $0.00 |
| Mar 9, 2026 | PERCEPTIVE ADVISORS | A | $50.0M |
| Feb 4, 2026 | Brooks Gabriel | SELL | $81.3K |
| Feb 4, 2026 | Herzich Paul | SELL | $70.2K |
8 institutional holders with $37.6M total value (6,667,268 shares) as of 2025-Q4. Top holders: VANGUARD, FMR, MORGAN. Net selling activity: 3 institutions trimmed/exited vs 2 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 3,454,959 | $19.5M | 51.8% | ADD +36.8% |
| 2 | FMR LLC | 2,029,898 | $11.4M | 30.4% | TRIM -30.3% |
| 3 | MORGAN STANLEY | 394,266 | $2.2M | 5.9% | ADD +52.9% |
| 4 | BANK OF AMERICA CORP /DE/ | 344,294 | $1.9M | 5.2% | TRIM -56.4% |
| 5 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 161,537 | $911.1K | 2.4% | DOUBLED +207.7% |
| 6 | TWO SIGMA INVESTMENTS, LP | 153,407 | $865.2K | 2.3% | DOUBLED +150.4% |
| 7 | WELLS FARGO & COMPANY/MN | 76,107 | $429.2K | 1.1% | ADD +68.4% |
| 8 | RENAISSANCE TECHNOLOGIES LLC | 52,800 | $297.8K | 0.8% | NEAR_EXIT -88.6% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| FMR LLC | TRIM | 2,914,127 | 2,029,898 | -30.3% | $11.4M | 2025-Q4 |
| MORGAN STANLEY | ADD | 257,846 | 394,266 | +52.9% | $2.2M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 789,996 | 344,294 | -56.4% | $1.9M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 45,207 | 76,107 | +68.4% | $429.2K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEAR_EXIT | 463,700 | 52,800 | -88.6% | $297.8K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 463,700 | — | $2.9M | 2025-Q3 |
| VANGUARD GROUP INC | ADD | 2,460,450 | 3,365,547 | +36.8% | $16.4M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 36,643 | 824,600 | +2150.4% | $4.0M | 2025-Q2 |
| UBS Group AG | DOUBLED | 114,695 | 772,295 | +573.3% | $3.8M | 2025-Q2 |
| MORGAN STANLEY | TRIM | 353,722 | 235,649 | -33.4% | $1.1M | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | DOUBLED | 68,607 | 211,074 | +207.7% | $1.0M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 69,494 | 174,000 | +150.4% | $847.4K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 14,141 | 42,362 | +199.6% | $206.3K | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 175,400 | 0 | -100.0% | $0.00 | 2025-Q2 |
| FMR LLC | DOUBLED | 46,705 | 3,517,888 | +7432.1% | $13.0M | 2025-Q1 |
| VANGUARD GROUP INC | ADD | 1,401,258 | 2,460,450 | +75.6% | $9.1M | 2025-Q1 |
| CITADEL ADVISORS LLC | ADD | 1,007,418 | 1,961,383 | +94.7% | $7.3M | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 77,983 | 353,722 | +353.6% | $1.3M | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 82,493 | 175,400 | +112.6% | $649.0K | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 136,145 | 69,494 | -49.0% | $257.1K | 2025-Q1 |
| UBS Group AG | DOUBLED | 11,996 | 94,467 | +687.5% | $377.9K | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 10,152 | 13,138 | +29.4% | $52.6K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 63,387 | — | $441.8K | 2024-Q3 |
9 unique insiders with 13 transactions. Net insider value: -$2.3M ($0.00 bought, $2.3M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 2, 2026 | SMITH IAN F | Director | M | 3,441 | $0.00 | $0.00 |
| Apr 2, 2026 | SMITH IAN F | Director | M | 3,441 | $0.00 | $0.00 |
| Mar 9, 2026 | PERCEPTIVE ADVISORS LLC | Director | A | 8,912,655 | $5.61 | $50.0M |
| Feb 4, 2026 | Brooks Gabriel | Chief Medical Officer | SELL | 12,616 | $6.44 | $81.3K |
| Feb 4, 2026 | Herzich Paul | Chief Technology Officer | SELL | 10,905 | $6.44 | $70.2K |
| Feb 4, 2026 | Cumbo Alexander | President and CEO | SELL | 48,913 | $6.44 | $315.1K |
| Feb 4, 2026 | Tan Kevin | CFO & Treasurer | SELL | 14,783 | $6.44 | $95.2K |
| Feb 4, 2026 | Hanrahan Jessie | Chief Regulatory Officer | SELL | 12,348 | $6.44 | $79.5K |
| Feb 4, 2026 | Howton David T | Chief Operating Officer | SELL | 18,894 | $6.44 | $121.7K |
| Feb 4, 2026 | Ganot Ilan | Director | SELL | 7,205 | $6.44 | $46.4K |
| Feb 2, 2026 | Hanrahan Jessie | Chief Regulatory Officer | SELL | 26,535 | $6.44 | $170.8K |
| Feb 2, 2026 | Howton David T | Chief Operating Officer | SELL | 37,771 | $6.44 | $243.1K |
| Feb 2, 2026 | Brooks Gabriel | Chief Medical Officer | SELL | 28,335 | $6.44 | $182.4K |
| Feb 2, 2026 | Tan Kevin | CFO & Treasurer | SELL | 26,837 | $6.44 | $172.7K |
| Feb 2, 2026 | Cumbo Alexander | President and CEO | SELL | 80,258 | $6.44 | $516.6K |
| Feb 2, 2026 | Herzich Paul | Chief Technology Officer | SELL | 26,250 | $6.44 | $169.0K |
| Jan 31, 2026 | Hanrahan Jessie | Chief Regulatory Officer | M | 27,625 | $0.00 | $0.00 |
| Jan 31, 2026 | Hanrahan Jessie | Chief Regulatory Officer | M | 27,625 | $0.00 | $0.00 |
| Jan 31, 2026 | Howton David T | Chief Operating Officer | M | 42,275 | $0.00 | $0.00 |
| Jan 31, 2026 | Howton David T | Chief Operating Officer | M | 42,275 | $0.00 | $0.00 |
| Jan 31, 2026 | Ganot Ilan | Director | M | 15,000 | $0.00 | $0.00 |
| Jan 31, 2026 | Ganot Ilan | Director | M | 15,000 | $0.00 | $0.00 |
| Jan 31, 2026 | Brooks Gabriel | Chief Medical Officer | M | 28,225 | $0.00 | $0.00 |
| Jan 31, 2026 | Brooks Gabriel | Chief Medical Officer | M | 28,225 | $0.00 | $0.00 |
| Jan 31, 2026 | Tan Kevin | CFO & Treasurer | M | 33,075 | $0.00 | $0.00 |
| Jan 31, 2026 | Tan Kevin | CFO & Treasurer | M | 33,075 | $0.00 | $0.00 |
| Jan 31, 2026 | Cumbo Alexander | President and CEO | M | 100,400 | $0.00 | $0.00 |
| Jan 31, 2026 | Cumbo Alexander | President and CEO | M | 100,400 | $0.00 | $0.00 |
| Jan 31, 2026 | Herzich Paul | Chief Technology Officer | M | 24,675 | $0.00 | $0.00 |
| Jan 31, 2026 | Herzich Paul | Chief Technology Officer | M | 24,675 | $0.00 | $0.00 |
| Jan 29, 2026 | Hanrahan Jessie | Chief Regulatory Officer | A | 95,000 | $0.00 | $0.00 |
| Jan 29, 2026 | Hanrahan Jessie | Chief Regulatory Officer | A | 190,000 | $0.00 | $0.00 |
| Jan 29, 2026 | Hanrahan Jessie | Chief Regulatory Officer | M | 54,925 | $0.00 | $0.00 |
| Jan 29, 2026 | Hanrahan Jessie | Chief Regulatory Officer | M | 54,925 | $0.00 | $0.00 |
| Jan 29, 2026 | Howton David T | Chief Operating Officer | A | 105,100 | $0.00 | $0.00 |
| Jan 29, 2026 | Howton David T | Chief Operating Officer | A | 210,200 | $0.00 | $0.00 |
| Jan 29, 2026 | Howton David T | Chief Operating Officer | M | 79,341 | $0.00 | $0.00 |
| Jan 29, 2026 | Howton David T | Chief Operating Officer | M | 79,341 | $0.00 | $0.00 |
| Jan 29, 2026 | Howton David T | Chief Operating Officer | A | 79,341 | $0.00 | $0.00 |
| Jan 29, 2026 | Hanrahan Jessie | Chief Regulatory Officer | A | 54,925 | $0.00 | $0.00 |
| Jan 29, 2026 | Brooks Gabriel | Chief Medical Officer | A | 58,847 | $0.00 | $0.00 |
| Jan 29, 2026 | Cumbo Alexander | President and CEO | A | 169,401 | $0.00 | $0.00 |
| Jan 29, 2026 | Herzich Paul | Chief Technology Officer | A | 54,925 | $0.00 | $0.00 |
| Jan 29, 2026 | Tan Kevin | CFO & Treasurer | A | 56,647 | $0.00 | $0.00 |
| Jan 29, 2026 | Ganot Ilan | Director | A | 70,900 | $0.00 | $0.00 |
| Jan 29, 2026 | Ganot Ilan | Director | A | 35,450 | $0.00 | $0.00 |
| Jan 29, 2026 | Brooks Gabriel | Chief Medical Officer | M | 58,847 | $0.00 | $0.00 |
| Jan 29, 2026 | Brooks Gabriel | Chief Medical Officer | M | 58,847 | $0.00 | $0.00 |
| Jan 29, 2026 | Brooks Gabriel | Chief Medical Officer | A | 207,450 | $0.00 | $0.00 |
| Jan 29, 2026 | Brooks Gabriel | Chief Medical Officer | A | 103,750 | $0.00 | $0.00 |
5 SEC filing reports analyzed. Sentiment: 1 bullish, 2 bearish, 0 mixed, 2 neutral. Avg impact: 5.2/10.
BEARISH
PRESS-RELEASE
6/10
Solid Biosciences reported Q1 2026 EPS of -$0.53, a 20.9% miss versus the -$0.44 consensus, with net
May 12, 2026
NEUTRAL
DEFA14A
3/10
Solid Biosciences is holding its 2026 annual meeting with several key proposals, including the ratif
Apr 23, 2026
NEUTRAL
8-K
2/10
Solid Biosciences Inc. announced a board seat reclassification for director Ilan Ganot, who resigned
Apr 10, 2026
BEARISH
EFFECT
7/10
Solid Biosciences Inc. has two S-3 shelf registration statements that became effective on March 31,
Apr 1, 2026
BULLISH
8-K
8/10
Solid Biosciences announced positive interim data from its Phase 1/2 INSPIRE DUCHENNE trial for SGT-
Mar 12, 2026
BULLISH
7/10
Solid Biosciences dosed the first participant in its Phase 3 IMPACT DUCHENNE trial for SGT-003, a ge
May 7, 2026
BULLISH
8/10
Solid Biosciences reported financial results for Q4 and full year 2025, highlighted by strong pipeli
Mar 19, 2026
BULLISH
8/10
Solid Biosciences reported updated positive interim data from its Phase 1/2 INSPIRE DUCHENNE trial f
Mar 11, 2026
NEUTRAL
6/10
Solid Biosciences (SLDB) announced a $240 million private placement through the sale of common stock
Mar 6, 2026
NEUTRAL
3/10
Solid Biosciences granted 17,600 restricted stock units (RSUs) to a newly hired employee as an induc
Mar 2, 2026
Current analyst consensus: Strong Buy (95% buy). Based on 20 analysts: 8 strong buy, 11 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$17.00 mean target
+159.2% upside
Strong Buy (1.29)
$11.00 Low
$26.00 High
| Metric | Value |
|---|---|
| Current Price | $6.56 |
| Target Low | $11.00 |
| Target Mean | $17.00 |
| Target Median | $16.00 |
| Target High | $26.00 |
| # Analysts | 13 |
| Recommendation | Strong Buy (1.29) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.47 | $-0.56 | $-0.36 | -11.9% | -14.9% | 2↑ 7↓ | $0.0B | 0.0% | 13 |
| Next Q 2026-09-30 |
$-0.48 | $-0.57 | $-0.39 | -0.6% | -14.0% | 2↑ 7↓ | $0.0B | 0.0% | 13 |
| Current FY 2026-12-31 |
$-1.98 | $-2.51 | $-1.67 | 0.5% | -15.0% | 1↑ 9↓ | $0.0B | 0.0% | 13 |
| Next FY 2027-12-31 |
$-1.93 | $-2.33 | $-1.36 | 2.7% | -14.4% | 1↑ 8↓ | $0.0B | 0.0% | 12 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.470 | |
| 7d ago | $0.000 | -0.470 |
| 30d ago | $-0.409 | -0.061 |
| 60d ago | $-0.464 | -0.006 |
| 90d ago | $-0.513 | +0.043 |
7 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 18, 2026 | Wedbush | REITERATE | Outperform | Outperform |
| May 13, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| May 13, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Mar 25, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Mar 23, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 20, 2026 | Guggenheim | INITIATE | — | Buy |
| Mar 20, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Mar 20, 2026 | Needham | REITERATE | Buy | Buy |
| Mar 12, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Mar 12, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Mar 11, 2026 | Wedbush | REITERATE | Outperform | Outperform |
| Feb 9, 2026 | Needham | REITERATE | Buy | Buy |
| Jan 14, 2026 | Needham | REITERATE | Buy | Buy |
| Dec 4, 2025 | Needham | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 8 | 11 | 1 | 0 | 0 | 95% | |
| Apr 1, 2026 | 8 | 11 | 1 | 0 | 0 | 95% | |
| Mar 1, 2026 | 7 | 11 | 1 | 0 | 0 | 95% | |
| Feb 1, 2026 | 7 | 11 | 1 | 0 | 0 | 95% | |
| Jan 1, 2026 | 7 | 12 | 1 | 0 | 0 | 95% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 14, 2026
short_volume
Short Volume: SLDB — 57.9% short (0.4M / 0.7M)
Short: 427,277 | Exempt: 842 | TRF Vol: 737,730 | Short Ratio: 57.9% | Off-exchange volume (dark pool + OTC)
May 13, 2026
earnings_calendar
SLDB Q1 2026 Earnings Scheduled — 2026-05-13
May 12, 2026
earnings
Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates
<p align="center"><em>-</em><strong><em> Duchenne (SGT-003):</em></strong><em> First participant dosed in the Phase 3 IMPACT DUCHENNE clinical trial,
May 7, 2026
fda
Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy
<p align="center"><em>- Initiation of Phase 3 IMPACT DUCHENNE placebo-controlled, randomized, double-blind trial as part of Solid’s integrated, multi-
May 1, 2026
other
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>CHARLESTOWN, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing pr
Apr 14, 2026
short_volume
Short Volume: SLDB — 66.8% short (0.6M / 0.8M)
Short: 560,888 | Exempt: 200 | TRF Vol: 840,181 | Short Ratio: 66.8% | Off-exchange volume (dark pool + OTC)
Mar 19, 2026
earnings
Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
<p align="center"><em>- <strong>Duchenne (SGT-003):</strong> Positive interim Phase 1/2 INSPIRE DUCHENNE data reported at the 2026 MDA Annual Meeting
Mar 11, 2026
fda
Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial
<p align="center"><em>- 40 participants have been dosed with SGT-003 in the INSPIRE DUCHENNE trial to date -</em></p>
Mar 6, 2026
offering
Solid Biosciences Announces Oversubscribed $240 Million Private Placement
<p>CHARLESTOWN, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision geneti
Mar 6, 2026
other
Solid Biosciences to Present at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
<p align="justify">CHARLESTOWN, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing
Mar 4, 2026
earnings_calendar
SLDB Q4 2025 Earnings After Market Close — 2026-03-04
Mar 2, 2026
regulatory
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>CHARLESTOWN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing